Siemens Healthineers: Analysts Hold Their Nerve as Sector Headwinds Batter the Stock

Siemens Healthineers shares slide 3% on GE HealthCare contagion, facing cost inflation, tariffs, and China headwinds; analysts see 53% upside potential.

The medical technology sector is feeling the heat, and Siemens Healthineers is caught in the crossfire without having fired a shot. When rival GE HealthCare tumbled more than 14 percent in US trading after a disappointing quarterly profit and a downgraded full-year outlook, the contagion spread fast. Siemens Healthineers shed nearly 3 percent in sympathy, while Philips lost close to 4 percent. The sell-off underscores just how interconnected the industry has become when cost pressures mount.

The Cost Crunch That Won't Quit

GE HealthCare's management blamed rising expenses for memory chips, oil, and freight for its earnings miss, warning that these headwinds would persist through 2026. That same cocktail of input cost inflation is now squarely in Siemens Healthineers' sights. But the German group faces additional burdens of its own: US tariffs are expected to weigh on EBIT to the tune of around €400 million, negative currency effects could reach €250 million, and planned cost-cutting measures in Germany's healthcare system are adding further strain.

The stock has been pummelled. After hitting a six-year low in late April, shares have lost roughly 21 percent since the start of the year. On Monday, the stock closed at €34.77, some 20 percent below its 200-day moving average — a technical signal that rarely inspires confidence.

Analysts See Opportunity in the Rubble

Despite the grim price action, not everyone is running for the exits. Barclays and JPMorgan have both maintained their buy ratings on Siemens Healthineers. Barclays analyst Hassan Al-Wakeel has a price target of €55, pointing to partner Eckert & Ziegler, which is doubling its capacity for key diagnostic components — a move that bolsters Siemens Healthineers' cancer therapy division. JPMorgan is even more bullish, with a target of €61.30, arguing that the negative scenario flagged by GE HealthCare's results is already largely priced into the stock.

The average analyst price target stands at around €53, implying significant upside from current levels. Shareholders are also banking on a slightly higher dividend of €1.01 for the current year.

China Remains the Elephant in the Room

When Siemens Healthineers reports its second-quarter results on May 7, all eyes will be on China. The diagnostics division shrank 3 percent in the first quarter amid persistent structural problems in the region, and management has already warned that second-quarter revenue growth will fall short of its 5 to 6 percent target range, with diagnostics in China again acting as a drag.

Group revenue did manage to climb 3.8 percent in the first quarter, reaching €5.4 billion, but adjusted earnings per share slipped 3 percent. The question now is whether the company can absorb the cost pressures that are squeezing the entire sector.

Demand Holds Up, Margins Under Siege

Barclays noted that GE HealthCare's imaging business actually beat revenue expectations, suggesting that underlying demand for medical technology remains robust. The problem, rather, lies on the cost side. Medical technology companies rely on complex supply chains, and rising prices for chips, energy, and logistics cannot be passed on to customers quickly.

Siemens Healthineers' management has so far stuck to its full-year guidance: comparable revenue growth of 5 to 6 percent and adjusted earnings per share between €2.20 and €2.40. Whether those targets survive contact with the second-quarter numbers will depend on how well the group has managed to absorb the cost headwinds — and whether China has any more unpleasant surprises in store.